Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collabor...

Ausführliche Beschreibung

Gespeichert in:

Bibliografische Detailangaben
Hauptverfasser:	S. G. P. Funnell, W. E. Dowling, C. Muñoz-Fontela, P.-S. Gsell, D. E. Ingber, G. A. Hamilton, L. Delang, J. Rocha-Pereira, S. Kaptein, K. H. Dallmeier, J. Neyts, K. Rosenke, E. de Wit, H. Feldmann, P. Maisonnasse, R. Le Grand, M. B. Frieman, C. M. Coleman
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Nature Portfolio 2020-08-01
Schriftenreihe:	Nature Communications
Online-Zugang:	https://doi.org/10.1038/s41467-020-17907-w
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Ähnliche Einträge